Fibroblast growth factor-1
Also known as: Acidic fibroblast growth factor, aFGF, ECGF, Endothelial cell growth factor, FGF-1, FGF‑1, FGF1, HBGF-1
Source Fibroblast growth factor-1 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Fibroblast growth factor‑1 (FGF‑1, also called acidic FGF) is a 155‑amino‑acid secreted protein that promotes mitogenesis, angiogenesis, and wound healing via FGFR activation.
Mechanism of Action
Binds to fibroblast growth factor receptors (FGFR1-4) in presence of heparan sulfate, activating MAPK/ERK and PI3K/AKT pathways leading to cell proliferation, angiogenesis, and tissue repair.
Routes of Administration
Goals & Uses
- Neural tissue repair and neuroprotectionNeurologyLow
- Angiogenesis promotion in coronary artery diseaseCardiovascularModerate
- Diabetic wound healingDermatology/MetabolicModerate
- Peripheral arterial disease / critical limb ischemiaVascularModerate
- Wound healingDermatologicModerateTissue repair and wound healing
- Metabolic syndrome / insulin sensitizationMetabolicLow
- Cardiac ischemia protectionCardiologyModerate
- Peripheral nerve regenerationNeurologicalLow
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Proliferative RetinopathyOphthalmologyModerate
- History of solid organ malignancyOncologyHigh
Adverse Effects
- ProteinuriaRenalUncommon
- Injection site reactionsLocalCommon
- HypotensionCardiovascularUnknownLow blood pressure
- Fever / flu-like symptomsSystemicUncommon
- Theoretical Oncogenic RiskOncologyUnknown
Drug Interactions
- HeparinLow
- Anticoagulants (warfarin, DOACs)Moderate
- Bevacizumab (anti-VEGF agents)Moderate
Population Constraints
- Patients with diabetes mellitus (with retinopathy)ComorbidityRelative
- Pediatric patientsAgeRelative
- Immunocompromised patientsImmunologicRelative
- Pregnant womenReproductiveRelative
- Patients with FGFR-mutant cancersOncology/GeneticAbsolute
Regulatory Status
- European UnionInvestigationalUnder clinical investigation for diabetic foot ulcer treatment.
- United StatesInvestigationalInvestigational use in clinical trials for wound healing.
- United KingdomUnknownNo MHRA-approved FGF-1 product identified; treated as investigational.
No FDA, EMA, or MHRA-approved therapeutic product based solely on FGF-1 as of 2024. Various recombinant forms and gene therapy vectors encoding FGF-1 have entered clinical trials (e.g., NV1FGF/Generx for coronary artery disease). Trafermin (recombinant FGF-2) is sometimes confused with FGF-1; they are distinct. Classified as a research/investigational agent.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Fibroblast growth factor-1?
Fibroblast growth factor‑1 (FGF‑1, also called acidic FGF) is a 155‑amino‑acid secreted protein that promotes mitogenesis, angiogenesis, and wound healing via FGFR activation.
What is Fibroblast growth factor-1 used for?
Fibroblast growth factor-1 is educationally associated with: Neural tissue repair and neuroprotection, Angiogenesis promotion in coronary artery disease, Diabetic wound healing, Peripheral arterial disease / critical limb ischemia, Wound healing, Metabolic syndrome / insulin sensitization, Cardiac ischemia protection, Peripheral nerve regeneration. Educational only — not medical advice.
How is Fibroblast growth factor-1 administered?
Recorded routes of administration: Intracoronary, Intramuscular, Intravenous, Subcutaneous, Topical.
What are the potential side effects of Fibroblast growth factor-1?
Reported adverse effects include: Proteinuria, Injection site reactions, Hypotension, Fever / flu-like symptoms, Theoretical Oncogenic Risk. This list is not exhaustive — consult a qualified clinician.
Who should avoid Fibroblast growth factor-1?
Recorded contraindications: Active malignancy, Pregnancy, Proliferative Retinopathy, History of solid organ malignancy. Consult a qualified clinician before use.